UNITED STATES | |
SECURITIES AND EXCHANGE COMMISSION | |
Washington, D.C. 20549 | |
Notice of Effectiveness | |
Effectiveness Date: | March 7, 2025 4:00 P.M. |
Form: | S-1 | ||||||
|
UNITED STATES | |
SECURITIES AND EXCHANGE COMMISSION | |
Washington, D.C. 20549 | |
Notice of Effectiveness | |
Effectiveness Date: | March 7, 2025 4:00 P.M. |
Form: | S-1 | ||||||
|
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/25/2025 | $50.00 → $55.00 | Overweight → Neutral | Analyst |
2/12/2025 | Outperform → Mkt Perform | William Blair | |
2/5/2025 | $58.00 → $74.00 | Buy | TD Cowen |
12/13/2024 | $60.00 | Outperform | Wolfe Research |
12/9/2024 | $74.00 | Buy | Guggenheim |
11/11/2024 | $45.00 → $65.00 | Buy → Hold | Stifel |
10/2/2024 | $45.00 → $60.00 | Buy → Neutral | BofA Securities |
8/12/2024 | $40.00 | Neutral | Piper Sandler |
4 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Reporting)
Analyst downgraded Tempus AI from Overweight to Neutral and set a new price target of $55.00 from $50.00 previously
William Blair downgraded Tempus AI from Outperform to Mkt Perform
TD Cowen resumed coverage of Tempus AI with a rating of Buy and set a new price target of $74.00 from $58.00 previously
EFFECT - Tempus AI, Inc. (0001717115) (Filer)
424B3 - Tempus AI, Inc. (0001717115) (Filer)
144 - Tempus AI, Inc. (0001717115) (Subject)
The kidSAFE certified app will offer kids and parents an alternative to gaming, social media and passive video consumption, reclaiming time for reading and creative play CHICAGO, March 5, 2025 /PRNewswire/ -- Wendy, a new kind of story company, has launched a children's story-building toolbox app that provides a safe and engaging story-building experience, helping children unlock their creativity and immersing them in endless possibilities for imaginative reading adventures. With kids' digital activity time rapidly increasing while literacy rates decrease, the Wendy app offers an engaging story-telling experience for kids to rediscover their love of reading. With the Wendy app, children par
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter and year ended December 31, 2024. Year-over-year revenue growth accelerated to 35.8% in the fourth quarter of 2024 Gross profit growth accelerated to 49.7% in the fourth quarter of 2024, led by Data and services Ended the year with $940 million in Total Remaining Contract Value and 140% net revenue retention Closed the acquisition of Ambry Genetics on February 3, 2025 Increases revenue guidance to $1.24 billion for 2024 and expect full year 2025 Adjusted EBITDA of approximately $5 million, an improvement
Up to 50% of patients with ER+/HER2- mBC could develop ESR1 mutations as a result of prior exposure to endocrine therapy in the metastatic setting. Testing to identify these mutations can help clinicians support more informed treatment-making decisions. The Next platform will analyze clinical data from mBC patients treated in certain centers and notify clinicians when ESR1 testing is missing at disease progression. CHICAGO and NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, and the Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics com
SC 13G - Tempus AI, Inc. (0001717115) (Subject)
SC 13G - Tempus AI, Inc. (0001717115) (Subject)
SC 13D/A - Tempus AI, Inc. (0001717115) (Filed by)
Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2024 on Monday, February 24, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 9601821 Domestic Dial-in Number: (888) 596-4144 International Dial-i
Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Monday, November 4, 2024. The company will hold the third quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The company's conference call that was previously scheduled for November 7, 2024 has been canceled. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the
Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Thursday, November 7, 2024. The company will hold the third quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 7177136 Domestic Dial-in Number: (800) 715-9871 International Dial-in